Home Cart Sign in  
Chemical Structure| 14259-47-3 Chemical Structure| 14259-47-3

Structure of Didymin
CAS No.: 14259-47-3

Chemical Structure| 14259-47-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Didymin, a natural product isolated and purified from the herbs of Clinopodium chinense with antioxidant property, may be a potential therapeutic molecule for the treatment of neurodegenerative disorders associated with oxidative stress.

Synonyms: Neoponcirin; Isosakuranetin-7-O-rutinoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Didymin

CAS No. :14259-47-3
Formula : C28H34O14
M.W : 594.56
SMILES Code : O=C1C[C@@H](C2=CC=C(OC)C=C2)OC3=CC(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO[C@H]5[C@@H]([C@@H]([C@H]([C@H](C)O5)O)O)O)O4)O)O)O)=CC(O)=C13
Synonyms :
Neoponcirin; Isosakuranetin-7-O-rutinoside
MDL No. :MFCD00151177

Safety of Didymin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Didymin

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical vein endothelial cells (HUVECs) 20 μM 24 h Pre-incubation with didymin prevented the release of various inflammatory cytokines and chemokines in HG-treated HUVECs. Biochem Pharmacol. 2018 Jun;152:1-10
Human umbilical vein endothelial cells (HUVECs) 20 μM 6 h Pre-incubation with didymin prevented HG-induced monocyte adhesion to endothelial cells and inhibited expressions of ICAM-1 and VCAM-1 and activation of NF-κB. Biochem Pharmacol. 2018 Jun;152:1-10
Human umbilical vein endothelial cells (HUVECs) 20 μM 3 h Pre-incubation with didymin prevented HG-induced generation of reactive oxygen species (ROS) and malondialdehyde (MDA). Biochem Pharmacol. 2018 Jun;152:1-10
Human umbilical vein endothelial cells (HUVECs) 10 μM and 20 μM 24 h Pre-incubation with didymin prevented high glucose (HG)-induced loss of cell viability. Biochem Pharmacol. 2018 Jun;152:1-10
H9c2 cardiomyocytes 5, 10, 20 μg/mL 4 h Did pretreatment significantly maintained cell viability and reduced LDH release, alleviating DOX-induced cell injury Chin Herb Med. 2021 Jul 15;14(1):70-78
INS-1 cells 50 µM 24 h To evaluate the effect of Didymin on insulin secretion function in INS-1 cells. Results showed that Didymin improved insulin secretion under high glucose stimulation, reduced excessive insulin secretion under low glucose stimulation, and increased intracellular insulin storage. Diabetol Metab Syndr. 2024 Jan 3;16(1):7
AML12 cells 50 μM 24 h To evaluate the effect of Didymin on PA-induced lipid deposition in AML12 cells. Results showed that Didymin significantly reduced PA-induced lipid accumulation. J Transl Med. 2023 Dec 19;21(1):921
MCF-7/ADR cells 10μM-200μM 48 h Evaluate the chemosensitization effect of Didymin and its inclusion complexes on drug-resistant tumor cells. Results showed that Didymin significantly increased intracellular accumulation of DOX in resistant cells and enhanced the cytotoxicity of DOX. Drug Deliv. 2020 Dec;27(1):54-65
PC12 cells 10μM-200μM 48 h Evaluate the toxicity of Didymin and its inclusion complexes on healthy cell lines. Results showed that cell viability remained above 90% at all tested concentrations, indicating low toxicity of Didymin and its inclusion complexes to healthy cells. Drug Deliv. 2020 Dec;27(1):54-65
H9C2 cells 10μM-200μM 48 h Evaluate the toxicity of Didymin and its inclusion complexes on healthy cell lines. Results showed that cell viability remained above 90% at all tested concentrations, indicating low toxicity of Didymin and its inclusion complexes to healthy cells. Drug Deliv. 2020 Dec;27(1):54-65
HUVEC cells 10μM-200μM 48 h Evaluate the toxicity of Didymin and its inclusion complexes on healthy cell lines. Results showed that cell viability remained above 90% at all tested concentrations, indicating low toxicity of Didymin and its inclusion complexes to healthy cells. Drug Deliv. 2020 Dec;27(1):54-65

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male BALB/c mice DOX-induced cardiotoxicity model Intraperitoneal injection 2, 4, 8 mg/kg Once daily for 7 days Did pretreatment significantly restored body weight, inhibited DOX-induced increase of LDH, CK, AST, and alleviated myocardial tissue injury and oxidative stress Chin Herb Med. 2021 Jul 15;14(1):70-78
C57BL/6J mice CCl4-induced liver fibrosis model Intragastric administration 2, 1, or 0.5 mg/kg 6 weeks Didymin significantly attenuated CCl4-induced hepatic injury and fibrogenesis, as evidenced by the ameliorative pathological tissue, low transaminase activity, and decreased collagen accumulation. Drug Des Devel Ther. 2022 Jun 7;16:1713-1729
C57BL/6J mice High-fat diet-induced impaired glucose tolerance (IGT) mouse model Intraperitoneal injection 0.8 mg/kg Once daily for three weeks To evaluate the effect of Didymin on pancreatic beta cell function in high-fat diet-induced IGT mice. Results showed that Didymin reduced postprandial glycemia and enhanced 30-minute postprandial insulin levels, improving pancreatic beta cell insulin secretion function. Diabetol Metab Syndr. 2024 Jan 3;16(1):7
C57BL/6J mice High-fat diet-induced MAFLD mouse model Intraperitoneal injection 0.8 mg/kg Once daily for three weeks To evaluate the therapeutic effect of Didymin on high-fat diet-induced MAFLD mice. Results showed that Didymin significantly reduced hepatic lipid deposition and serum lipid levels. J Transl Med. 2023 Dec 19;21(1):921
SD rats Not used Oral 25 mg/kg Single dose Evaluate the pharmacokinetic properties of Didymin and its inclusion complexes. Results showed that the bioavailability of Didymin/HP-β-CD inclusion complex was significantly higher than that of free Didymin and Didymin/β-CD inclusion complex. Drug Deliv. 2020 Dec;27(1):54-65

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.41mL

1.68mL

0.84mL

16.82mL

3.36mL

1.68mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories